ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
ARVO 2020 clinical trial results presentation by Stephen Russel et al. Sepofarsen had a manageable safety profile and showed improvement in mean visual acuity, and full-field stimulus testing.
Featuring Dr. Byron Lam, Professor, Bascom Palmer Eye Institute, University of Miami School of Medicine
Hosted by Cantor Biotechnology Analysts Emma Nealon, Alethia Young